Zai Lab

ZLAB · HONG

$24.03+$1.99 (+9.03%)TodayMarket closed · Oct 23, 7:39 PM ET

Prev close $22.04

ZLAB analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $29.31 (+22.0% upside)

Low: $20.21
Now: $24.03
High: $39.14

Upgrades and downgrades

The latest rating actions, newest first

ZLAB analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Aug 7, 2026	Maintains	Buy	$44.00 → $45.00	43%
Citigroup	May 8, 2026	Maintains	Buy	$47.00 → $44.00	43%
JP Morgan	Mar 18, 2026	Maintains	Overweight	$39.00 → $32.00	48%
Cantor Fitzgerald	Feb 27, 2026	Maintains	Overweight	$55.00 → $37.00	51%
JP Morgan	Feb 5, 2026	Maintains	Overweight	$46.00 → $39.00	48%
UBS	Jan 7, 2026	Initiates	Buy	$35.00	54%

The case for and against

Updated Jan 25, 2025

Bull case

Zai Lab Ltd's positive outlook is bolstered by the improved efficacy and safety of its investigational therapies, particularly ZL-1310, which has demonstrated strong potential in treating advanced-stage small cell lung cancer (SCLC), leading to a recent spike in stock performance following favorable first-in-human data. The company's diverse portfolio, including proprietary drug candidates like ZL-2306, ZL-2401, and ZL-2301, addresses significant unmet medical needs in oncology and infectious diseases, suggesting substantial market opportunities that may not yet be fully reflected in its current valuation. Furthermore, the competitive landscape, highlighted by recent FDA approvals for similar therapies, emphasizes the importance of Zai Lab's advancements and their potential to capture market share in the growing biopharmaceutical sector.

Bear case

Zai Lab Ltd. faces significant challenges in successfully commercializing its products due to extensive competition from larger pharmaceutical companies that possess robust sales and marketing resources, potentially leading to higher risks, longer timelines, and increased costs for Zai Lab. Additionally, the company has limited experience in product commercialization, which further complicates its ability to compete effectively in a crowded market. Lastly, uncertainties within the Chinese legal system could negatively impact Zai Lab's operational stability and investment attractiveness, adding to the concerns surrounding its market position and future growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.